This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
NBTXR3 is designed as a radio-sensitizer for the treatment of solid tumors. The drug is made of 50 nm nano-particles composed of an inorganic core of crystallized hafnium oxide. It is injected directly into tumors and is proposed to accumulate in tumor cells and amplify the lethal energy of xrays through the accumulation of free electrons.
MedDeviceTracker maintains a separate profile for the European development of NBTXR3, as it is classified as a device outside the U.S.
NBTXR3 (Drug) News
Additional information available to subscribers only: